Effects of Angiogenesis Inhibitor SU5416 on Microvessel Density in Rat Model of Pancreatic CancerDepartment of General Surgery, The People’s Hospital of Songgang, Shenzhen 518105, China_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

WANG Zhaochun ¹ , SHI Lizhi ² , CHEN Ziping ² , ZOU Guihua ² , SUO Jian. ³

Corresponding author：

Keywords：

Pancreatic cancer; Microvascular density; Angiogenesis inhibitor

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

ObjectiveTo study the effects of angiogenesis inhibitor SU5416 on the microvessel density(MVD) of pancreatic cancer and to evaluate its influence on the growth and metastasis of pancreatic cancer. Methods A rat model of pancreatic cancer was established with dimethylbenzanthracine(DMBA). 60 rats with pancreatic cancer were randomly divided into 4 groups: saline group, 5-Fu group, SU5416 group, 5-Fu and SU5416 group. Thirteen weeks after injection, the microvascular density (MVD) of pancreatic cancer was detected.Results The microvascular densities (MVD) were (12.3±3.2)%, (11.4±3.8)%, (2.1±1.5)% and (1.8±1.1)% in the saline group, 5-Fu group, SU5416 group and 5-Fu+SU5416 group respectively. The MVDs in the SU5416 group and 5Fu+SU5416 group were statistically lower than those in the saline group and 5-Fu group(P＜0.05). There was no significant difference between the 5-Fu group and saline group(P gt;0.05). ConclusionSU5416 can inhibit the microvascular growth in pancreatic cancer. And the inhibition can be enhanced when combined with chemotheraputic drugs.

Citation： WANG Zhaochun,SHI Lizhi,CHEN Ziping,ZOU Guihua,SUO Jian.. Effects of Angiogenesis Inhibitor SU5416 on Microvessel Density in Rat Model of Pancreatic CancerDepartment of General Surgery, The People’s Hospital of Songgang, Shenzhen 518105, China. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2004, 11(4): 351-352. doi: Copy

1.	秦仁义, 爱德, 邹声泉,等. 一种新型大鼠胰腺癌模型的制备 [Ｊ]. 中国实验外科杂志, 2000; 17(5)∶ 462.
2.	傅德良, 倪泉兴. 胰腺癌的早期诊断和治疗进展 [Ｊ]. 中国临床医学, 2000; 7(1)∶107.
3.	Yancopoulos AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis [Ｊ]. Natl Cancer Inst, 1997; 89(4)∶1260.
4.	Fanelli M, Loeopo N, Gattuso D, et al. Assessment of tumor vascularization: immunohistochemical and noninvasive methods [Ｊ]. Int J Biol Markers, 1999; 14(3)∶218.
5.	Mendel DB, Laird AD, Smolich BD, et al. Development of SU5416, A selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an antiangiogenesis agent [Ｊ]. Anticancer Drug Des, 2000; 15(1)∶29.
6.	Fong TA, Shawver LK, Sun L, et al. SU5146 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types [Ｊ]. Cancer Res, 1999; 59(2)∶99.
7.	张国锋, 王元和, 王强,等. SU5146抑制胃癌生长和肝转移的实验研究 [Ｊ].中华消化杂志, 2002; 22(4)∶213.

1. 秦仁义, 爱德, 邹声泉,等. 一种新型大鼠胰腺癌模型的制备 [Ｊ]. 中国实验外科杂志, 2000; 17(5)∶ 462.
2. 傅德良, 倪泉兴. 胰腺癌的早期诊断和治疗进展 [Ｊ]. 中国临床医学, 2000; 7(1)∶107.
3. Yancopoulos AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis [Ｊ]. Natl Cancer Inst, 1997; 89(4)∶1260.
4. Fanelli M, Loeopo N, Gattuso D, et al. Assessment of tumor vascularization: immunohistochemical and noninvasive methods [Ｊ]. Int J Biol Markers, 1999; 14(3)∶218.
5. Mendel DB, Laird AD, Smolich BD, et al. Development of SU5416, A selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an antiangiogenesis agent [Ｊ]. Anticancer Drug Des, 2000; 15(1)∶29.
6. Fong TA, Shawver LK, Sun L, et al. SU5146 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types [Ｊ]. Cancer Res, 1999; 59(2)∶99.
7. 张国锋, 王元和, 王强,等. SU5146抑制胃癌生长和肝转移的实验研究 [Ｊ].中华消化杂志, 2002; 22(4)∶213.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Effects of Angiogenesis Inhibitor SU5416 on Microvessel Density in Rat Model of Pancreatic CancerDepartment of General Surgery, The People’s Hospital of Songgang, Shenzhen 518105, China

Abstract Full text Figures/Tables Video References Cited by

Format

Content